Skip to main content
PMC home page
Molecular Medicine logoLink to Molecular Medicine
. 1998 Oct;4(10):671–674.

No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus.

L Naylor 1, B Dean 1, A Pereira 1, A Mackinnon 1, A Kouzmenko 1, D Copolov 1
PMCID: PMC2230253  PMID: 9848084

Abstract

BACKGROUND: Allelic association case-control analysis of a deletion/insertion polymorphism in the serotonin transporter-linked polymorphic region (5-HTTLPR) has suggested associations with unipolar disorder, bipolar disorder, depression, and Alzheimer's disease. Moreover, the heterozygous long form of the 5-HTTLPR has been associated with increased levels of mRNA for the serotonin transporter (5-HTT) and increased serotonin uptake in lymphoblastic cell lines. This study attempts to determine whether there is an association between 5-HTTLPR genotype and schizophrenia or the binding of [3H]paroxetine to the human hippocampal 5-HTT. MATERIALS AND METHODS: DNA from the cerebellum from 58 schizophrenic and 62 control subjects was used to genotype the 5-HTTLPR. In addition, the relationship between 5-HTTLPR genotype and the affinity and density of [3H]paroxetine binding to the hippocampal 5-HTT was assessed. RESULTS: There were no associations between 5-HTTLPR allotype or genotype and/or the parameters of [3H]paroxetine binding to the hippocampal 5-HTT. CONCLUSIONS: Our data suggest that 5-HTTLPR genotype neither confers an increased susceptibility for schizophrenia nor dictates the expression of the 5-HTT in the human hippocampus.

Full text

PDF
672

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collier D. A., Stöber G., Li T., Heils A., Catalano M., Di Bella D., Arranz M. J., Murray R. M., Vallada H. P., Bengel D. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry. 1996 Dec;1(6):453–460. [PubMed] [Google Scholar]
  2. Dean B., Opeskin K., Pavey G., Naylor L., Hill C., Keks N., Copolov D. L. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem. 1995 Mar;64(3):1197–1202. doi: 10.1046/j.1471-4159.1995.64031197.x. [DOI] [PubMed] [Google Scholar]
  3. Furlong R. A., Ho L., Walsh C., Rubinsztein J. S., Jain S., Paykel E. S., Easton D. F., Rubinsztein D. C. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet. 1998 Feb 7;81(1):58–63. [PubMed] [Google Scholar]
  4. Hill C., Keks N., Roberts S., Opeskin K., Dean B., MacKinnon A., Copolov D. Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry. 1996 Apr;153(4):533–537. doi: 10.1176/ajp.153.4.533. [DOI] [PubMed] [Google Scholar]
  5. Kendler K. S., Diehl S. R. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull. 1993;19(2):261–285. doi: 10.1093/schbul/19.2.261. [DOI] [PubMed] [Google Scholar]
  6. Lesch K. P., Balling U., Gross J., Strauss K., Wolozin B. L., Murphy D. L., Riederer P. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994;95(2):157–162. doi: 10.1007/BF01276434. [DOI] [PubMed] [Google Scholar]
  7. Lesch K. P., Bengel D., Heils A., Sabol S. Z., Greenberg B. D., Petri S., Benjamin J., Müller C. R., Hamer D. H., Murphy D. L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996 Nov 29;274(5292):1527–1531. doi: 10.1126/science.274.5292.1527. [DOI] [PubMed] [Google Scholar]
  8. Li T., Holmes C., Sham P. C., Vallada H., Birkett J., Kirov G., Lesch K. P., Powell J., Lovestone S., Collier D. Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease. Neuroreport. 1997 Feb 10;8(3):683–686. doi: 10.1097/00001756-199702100-00021. [DOI] [PubMed] [Google Scholar]
  9. Meltzer H. Serotonergic dysfunction in depression. Br J Psychiatry Suppl. 1989 Dec;(8):25–31. [PubMed] [Google Scholar]
  10. Mendes de Oliveira J. R., Otto P. A., Vallada H., Lauriano V., Elkis H., Lafer B., Vasquez L., Gentil V., Passos-Bueno M. R., Zatz M. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. Am J Med Genet. 1998 May 8;81(3):225–227. doi: 10.1002/(sici)1096-8628(19980508)81:3<225::aid-ajmg4>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  11. Naylor L., Dean B., Opeskin K., Pavey G., Hill C., Keks N., Copolov D. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J Neural Transm (Vienna) 1996;103(6):749–757. doi: 10.1007/BF01271234. [DOI] [PubMed] [Google Scholar]
  12. Sasieni P. D. From genotypes to genes: doubling the sample size. Biometrics. 1997 Dec;53(4):1253–1261. [PubMed] [Google Scholar]
  13. Stöber G., Jatzke S., Heils A., Jungkunz G., Fuchs E., Knapp M., Riederer P., Lesch K. P. Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene. Eur Arch Psychiatry Clin Neurosci. 1998;248(2):82–86. doi: 10.1007/s004060050022. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES